Market Analysis and Insights: Global Viral Vector-Based Gene Therapy Market
The global Viral Vector-Based Gene Therapy market is projected to grow from US$ million in 2023 to US$ million by 2029, at a Compound Annual Growth Rate (CAGR) of % during the forecast period.
The US & Canada market for Viral Vector-Based Gene Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The China market for Viral Vector-Based Gene Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The Europe market for Viral Vector-Based Gene Therapy is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global key companies of Viral Vector-Based Gene Therapy include Sibiono, Rigvir Group, Shanghai Pharma (Sunway), Amgen, Spark Therapeutics, Novartis Gene Therapies, Daiichi Sankyo and PTC Therapeutics, etc. in 2022, the global top five players had a share approximately % in terms of revenue.
Report Includes
This report presents an overview of global market for Viral Vector-Based Gene Therapy market size. Analyses of the global market trends, with historic market revenue data for 2018 - 2022, estimates for 2023, and projections of CAGR through 2029.
This report researches the key producers of Viral Vector-Based Gene Therapy, also provides the revenue of main regions and countries. Highlights of the upcoming market potential for Viral Vector-Based Gene Therapy, and key regions/countries of focus to forecast this market into various segments and sub-segments. Country specific data and market value analysis for the U.S., Canada, Mexico, Brazil, China, Japan, South Korea, Southeast Asia, India, Germany, the U.K., Italy, Middle East, Africa, and Other Countries.
This report focuses on the Viral Vector-Based Gene Therapy revenue, market share and industry ranking of main companies, data from 2018 to 2023. Identification of the major stakeholders in the global Viral Vector-Based Gene Therapy market, and analysis of their competitive landscape and market positioning based on recent developments and segmental revenues. This report will help stakeholders to understand the competitive landscape and gain more insights and position their businesses and market strategies in a better way.
This report analyzes the segments data by type and by application, revenue, and growth rate, from 2018 to 2029. Evaluation and forecast the market size for Viral Vector-Based Gene Therapy revenue, projected growth trends, production technology, application and end-user industry.
Descriptive company profiles of the major global players, including Sibiono, Rigvir Group, Shanghai Pharma (Sunway), Amgen, Spark Therapeutics, Novartis Gene Therapies, Daiichi Sankyo and PTC Therapeutics, etc.
By Company
Sibiono
Rigvir Group
Shanghai Pharma (Sunway)
Amgen
Spark Therapeutics
Novartis Gene Therapies
Daiichi Sankyo
PTC Therapeutics
Segment by Type
Adenovirus (AdV)
Adeno-associated Virus (AAV)
Segment by Application
Hospital
Clinic
Others
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East, Africa, and Latin America
Turkey
Saudi Arabia
UAE
Rest of MEA
Chapter Outline
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (product type, application, etc.), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Revenue of Viral Vector-Based Gene Therapy in global and regional level. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world. This section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Viral Vector-Based Gene Therapy companies’ competitive landscape, revenue, market share and industry ranking, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the revenue, and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6: North America by type, by application and by country, revenue for each segment.
Chapter 7: Europe by type, by application and by country, revenue for each segment.
Chapter 8: China by type and by application revenue for each segment.
Chapter 9: Asia (excluding China) by type, by application and by region, revenue for each segment.
Chapter 10: Middle East, Africa, and Latin America by type, by application and by country, revenue for each segment.
Chapter 11: Provides profiles of key companies, introducing the basic situation of the main companies in the market in detail, including product descriptions and specifications, Viral Vector-Based Gene Therapy revenue, gross margin, and recent development, etc.
Chapter 12: Analyst's Viewpoints/Conclusions
Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.
1 Report Overview
1.1 Study Scope
1.2 Market Analysis by Type
1.2.1 Global Viral Vector-Based Gene Therapy Market Size Growth Rate by Type, 2018 VS 2022 VS 2029
1.2.2 Adenovirus (AdV)
1.2.3 Adeno-associated Virus (AAV)
1.3 Market by Application
1.3.1 Global Viral Vector-Based Gene Therapy Market Size Growth Rate by Application, 2018 VS 2022 VS 2029
1.3.2 Hospital
1.3.3 Clinic
1.3.4 Others
1.4 Assumptions and Limitations
1.5 Study Objectives
1.6 Years Considered
2 Global Growth Trends
2.1 Global Viral Vector-Based Gene Therapy Market Perspective (2018-2029)
2.2 Global Viral Vector-Based Gene Therapy Growth Trends by Region
2.2.1 Viral Vector-Based Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
2.2.2 Viral Vector-Based Gene Therapy Historic Market Size by Region (2018-2023)
2.2.3 Viral Vector-Based Gene Therapy Forecasted Market Size by Region (2024-2029)
2.3 Viral Vector-Based Gene Therapy Market Dynamics
2.3.1 Viral Vector-Based Gene Therapy Industry Trends
2.3.2 Viral Vector-Based Gene Therapy Market Drivers
2.3.3 Viral Vector-Based Gene Therapy Market Challenges
2.3.4 Viral Vector-Based Gene Therapy Market Restraints
3 Competition Landscape by Key Players
3.1 Global Revenue Viral Vector-Based Gene Therapy by Players
3.1.1 Global Viral Vector-Based Gene Therapy Revenue by Players (2018-2023)
3.1.2 Global Viral Vector-Based Gene Therapy Revenue Market Share by Players (2018-2023)
3.2 Global Viral Vector-Based Gene Therapy Market Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Global Key Players of Viral Vector-Based Gene Therapy, Ranking by Revenue, 2021 VS 2022 VS 2023
3.4 Global Viral Vector-Based Gene Therapy Market Concentration Ratio
3.4.1 Global Viral Vector-Based Gene Therapy Market Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Viral Vector-Based Gene Therapy Revenue in 2022
3.5 Global Key Players of Viral Vector-Based Gene Therapy Head office and Area Served
3.6 Global Key Players of Viral Vector-Based Gene Therapy, Product and Application
3.7 Global Key Players of Viral Vector-Based Gene Therapy, Date of Enter into This Industry
3.8 Mergers & Acquisitions, Expansion Plans
4 Viral Vector-Based Gene Therapy Breakdown Data by Type
4.1 Global Viral Vector-Based Gene Therapy Historic Market Size by Type (2018-2023)
4.2 Global Viral Vector-Based Gene Therapy Forecasted Market Size by Type (2024-2029)
5 Viral Vector-Based Gene Therapy Breakdown Data by Application
5.1 Global Viral Vector-Based Gene Therapy Historic Market Size by Application (2018-2023)
5.2 Global Viral Vector-Based Gene Therapy Forecasted Market Size by Application (2024-2029)
6 North America
6.1 North America Viral Vector-Based Gene Therapy Market Size (2018-2029)
6.2 North America Viral Vector-Based Gene Therapy Market Size by Type
6.2.1 North America Viral Vector-Based Gene Therapy Market Size by Type (2018-2023)
6.2.2 North America Viral Vector-Based Gene Therapy Market Size by Type (2024-2029)
6.2.3 North America Viral Vector-Based Gene Therapy Market Share by Type (2018-2029)
6.3 North America Viral Vector-Based Gene Therapy Market Size by Application
6.3.1 North America Viral Vector-Based Gene Therapy Market Size by Application (2018-2023)
6.3.2 North America Viral Vector-Based Gene Therapy Market Size by Application (2024-2029)
6.3.3 North America Viral Vector-Based Gene Therapy Market Share by Application (2018-2029)
6.4 North America Viral Vector-Based Gene Therapy Market Size by Country
6.4.1 North America Viral Vector-Based Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
6.4.2 North America Viral Vector-Based Gene Therapy Market Size by Country (2018-2023)
6.4.3 North America Viral Vector-Based Gene Therapy Market Size by Country (2024-2029)
6.4.4 United States
6.4.5 Canada
7 Europe
7.1 Europe Viral Vector-Based Gene Therapy Market Size (2018-2029)
7.2 Europe Viral Vector-Based Gene Therapy Market Size by Type
7.2.1 Europe Viral Vector-Based Gene Therapy Market Size by Type (2018-2023)
7.2.2 Europe Viral Vector-Based Gene Therapy Market Size by Type (2024-2029)
7.2.3 Europe Viral Vector-Based Gene Therapy Market Share by Type (2018-2029)
7.3 Europe Viral Vector-Based Gene Therapy Market Size by Application
7.3.1 Europe Viral Vector-Based Gene Therapy Market Size by Application (2018-2023)
7.3.2 Europe Viral Vector-Based Gene Therapy Market Size by Application (2024-2029)
7.3.3 Europe Viral Vector-Based Gene Therapy Market Share by Application (2018-2029)
7.4 Europe Viral Vector-Based Gene Therapy Market Size by Country
7.4.1 Europe Viral Vector-Based Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
7.4.2 Europe Viral Vector-Based Gene Therapy Market Size by Country (2018-2023)
7.4.3 Europe Viral Vector-Based Gene Therapy Market Size by Country (2024-2029)
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia
7.4.8 Nordic Countries
8 China
8.1 China Viral Vector-Based Gene Therapy Market Size (2018-2029)
8.2 China Viral Vector-Based Gene Therapy Market Size by Type
8.2.1 China Viral Vector-Based Gene Therapy Market Size by Type (2018-2023)
8.2.2 China Viral Vector-Based Gene Therapy Market Size by Type (2024-2029)
8.2.3 China Viral Vector-Based Gene Therapy Market Share by Type (2018-2029)
8.3 China Viral Vector-Based Gene Therapy Market Size by Application
8.3.1 China Viral Vector-Based Gene Therapy Market Size by Application (2018-2023)
8.3.2 China Viral Vector-Based Gene Therapy Market Size by Application (2024-2029)
8.3.3 China Viral Vector-Based Gene Therapy Market Share by Application (2018-2029)
9 Asia (excluding China)
9.1 Asia Viral Vector-Based Gene Therapy Market Size (2018-2029)
9.2 Asia Viral Vector-Based Gene Therapy Market Size by Type
9.2.1 Asia Viral Vector-Based Gene Therapy Market Size by Type (2018-2023)
9.2.2 Asia Viral Vector-Based Gene Therapy Market Size by Type (2024-2029)
9.2.3 Asia Viral Vector-Based Gene Therapy Market Share by Type (2018-2029)
9.3 Asia Viral Vector-Based Gene Therapy Market Size by Application
9.3.1 Asia Viral Vector-Based Gene Therapy Market Size by Application (2018-2023)
9.3.2 Asia Viral Vector-Based Gene Therapy Market Size by Application (2024-2029)
9.3.3 Asia Viral Vector-Based Gene Therapy Market Share by Application (2018-2029)
9.4 Asia Viral Vector-Based Gene Therapy Market Size by Region
9.4.1 Asia Viral Vector-Based Gene Therapy Market Size by Region: 2018 VS 2022 VS 2029
9.4.2 Asia Viral Vector-Based Gene Therapy Market Size by Region (2018-2023)
9.4.3 Asia Viral Vector-Based Gene Therapy Market Size by Region (2024-2029)
9.4.4 Japan
9.4.5 South Korea
9.4.6 China Taiwan
9.4.7 Southeast Asia
9.4.8 India
9.4.9 Australia
10 Middle East, Africa, and Latin America
10.1 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Size (2018-2029)
10.2 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Size by Type
10.2.1 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Size by Type (2018-2023)
10.2.2 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Size by Type (2024-2029)
10.2.3 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Share by Type (2018-2029)
10.3 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Size by Application
10.3.1 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Size by Application (2018-2023)
10.3.2 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Size by Application (2024-2029)
10.3.3 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Share by Application (2018-2029)
10.4 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Size by Country
10.4.1 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Size by Country: 2018 VS 2022 VS 2029
10.4.2 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Size by Country (2018-2023)
10.4.3 Middle East, Africa, and Latin America Viral Vector-Based Gene Therapy Market Size by Country (2024-2029)
10.4.4 Brazil
10.4.5 Mexico
10.4.6 Turkey
10.4.7 Saudi Arabia
10.4.8 Israel
10.4.9 GCC Countries
11 Key Players Profiles
11.1 Sibiono
11.1.1 Sibiono Company Details
11.1.2 Sibiono Business Overview
11.1.3 Sibiono Viral Vector-Based Gene Therapy Introduction
11.1.4 Sibiono Revenue in Viral Vector-Based Gene Therapy Business (2018-2023)
11.1.5 Sibiono Recent Developments
11.2 Rigvir Group
11.2.1 Rigvir Group Company Details
11.2.2 Rigvir Group Business Overview
11.2.3 Rigvir Group Viral Vector-Based Gene Therapy Introduction
11.2.4 Rigvir Group Revenue in Viral Vector-Based Gene Therapy Business (2018-2023)
11.2.5 Rigvir Group Recent Developments
11.3 Shanghai Pharma (Sunway)
11.3.1 Shanghai Pharma (Sunway) Company Details
11.3.2 Shanghai Pharma (Sunway) Business Overview
11.3.3 Shanghai Pharma (Sunway) Viral Vector-Based Gene Therapy Introduction
11.3.4 Shanghai Pharma (Sunway) Revenue in Viral Vector-Based Gene Therapy Business (2018-2023)
11.3.5 Shanghai Pharma (Sunway) Recent Developments
11.4 Amgen
11.4.1 Amgen Company Details
11.4.2 Amgen Business Overview
11.4.3 Amgen Viral Vector-Based Gene Therapy Introduction
11.4.4 Amgen Revenue in Viral Vector-Based Gene Therapy Business (2018-2023)
11.4.5 Amgen Recent Developments
11.5 Spark Therapeutics
11.5.1 Spark Therapeutics Company Details
11.5.2 Spark Therapeutics Business Overview
11.5.3 Spark Therapeutics Viral Vector-Based Gene Therapy Introduction
11.5.4 Spark Therapeutics Revenue in Viral Vector-Based Gene Therapy Business (2018-2023)
11.5.5 Spark Therapeutics Recent Developments
11.6 Novartis Gene Therapies
11.6.1 Novartis Gene Therapies Company Details
11.6.2 Novartis Gene Therapies Business Overview
11.6.3 Novartis Gene Therapies Viral Vector-Based Gene Therapy Introduction
11.6.4 Novartis Gene Therapies Revenue in Viral Vector-Based Gene Therapy Business (2018-2023)
11.6.5 Novartis Gene Therapies Recent Developments
11.7 Daiichi Sankyo
11.7.1 Daiichi Sankyo Company Details
11.7.2 Daiichi Sankyo Business Overview
11.7.3 Daiichi Sankyo Viral Vector-Based Gene Therapy Introduction
11.7.4 Daiichi Sankyo Revenue in Viral Vector-Based Gene Therapy Business (2018-2023)
11.7.5 Daiichi Sankyo Recent Developments
11.8 PTC Therapeutics
11.8.1 PTC Therapeutics Company Details
11.8.2 PTC Therapeutics Business Overview
11.8.3 PTC Therapeutics Viral Vector-Based Gene Therapy Introduction
11.8.4 PTC Therapeutics Revenue in Viral Vector-Based Gene Therapy Business (2018-2023)
11.8.5 PTC Therapeutics Recent Developments
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details
Sibiono
Rigvir Group
Shanghai Pharma (Sunway)
Amgen
Spark Therapeutics
Novartis Gene Therapies
Daiichi Sankyo
PTC Therapeutics
*If Applicable.